Production, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as a bone pain palliation agent

Production, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as a bone pain palliation agent

Show other versions (1)

Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluate...

Full description

Bibliographic Details
Main Authors:	samaneh zolghadri, hassan yousefnia, amir reza jalilian, mohammad ghannadi-maragheh
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2015-01-01
Series:	Asia Oceania Journal of Nuclear Medicine and Biology
Subjects:	Bone pain palliation Lu-177 TTHMP Dosimetry
Online Access:	http://aojnmb.mums.ac.ir/pdf_2840_6edada16b7d9f6096d15ece428960ac3.html

Similar Items

Production, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as a bone pain palliation agent
by: samaneh zolghadri, et al.
Published: (2015-01-01)

Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent
by: Samaneh Zolghadri, et al.
Published: (2015-06-01)

Tissue dose estimation after extravasation of 177Lu-DOTATATE
by: Perrine Tylski, et al.
Published: (2021-03-01)

[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
by: Madhav Prasad Yadav, et al.
Published: (2020-10-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Extravasation of [177Lu]Lu-DOTATOC: case report and discussion
by: Anne Kirstine Arveschoug, et al.
Published: (2020-06-01)

Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results
by: Ambreen Khawar, et al.
Published: (2019-11-01)

Metastatic Bone Pain Palliation using 177 Lu-Ethylenediaminetetramethylene Phosphonic Acid
by: Mehrosadat Alavi, et al.
Published: (2015-01-01)

Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
by: Lore Santoro, et al.
Published: (2021-01-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Cinética e dosimetria do [177Lu-DOTA0, Tyr3]octreotato em pacientes com tumores carcinoides
by: Ana Claudia Machado Silva
Published: (2014)

Cinética e dosimetria do [177Lu-DOTA0, Tyr3]octreotato em pacientes com tumores carcinoides
by: Silva, Ana Claudia Machado
Published: (2014)

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
by: Alessandro Desy, et al.
Published: (2020-05-01)

Development of 177Lu-phytate Complex for Radiosynovectomy
by: Hassan Yousefnia, et al.
Published: (2013-05-01)

Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
by: Mattias Sandström, et al.
Published: (2020-12-01)

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01)

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report
by: Alexis Huot Daneault, et al.
Published: (2021-07-01)

Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
by: Giulia Tamborino, et al.
Published: (2020-02-01)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
by: Andreas Rinscheid, et al.
Published: (2020-06-01)

Dosimetry of Radionuclide Therapy with 177Lu-octreotate
by: Sandström, Mattias
Published: (2011)

Deadtime effects in quantification of 177Lu activity for radionuclide therapy
by: Carlos F. Uribe, et al.
Published: (2018-01-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
by: Pretoria Bilinski, et al.
Published: (2021-01-01)

Preparation and Preliminary Biological Evaluation of 177Lu Labelled Rituximab
by: MA Xiu-feng1;ZHANG Jun-li2;LI Hong-yu1,2;LIANG Ji-xin1;YANG Yun2;YANG Chun-hui2;DU Jin1,3
Published: (2014-02-01)

Correlation of An Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
by: Johannes Zellmer, et al.
Published: (2020-04-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Terapia com [177Lu – Dota0 – Tyr3]–Octreotate (177Lu-Dotatate) em Pacientes com Tumores Avançados de Origem Neuroendócrino: Experiência Inicial e Resultados Preliminares
by: Víctor Marín Oyaga, et al.
Published: (2017-10-01)

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021-08-01)

Comparative Therapeutic Efficacy of 153Sm-EDTMP and 177Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients’ Pain Score Analysis and Personalized Dosimetry
by: Baljinder Singh, et al.
Published: (2017-05-01)

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE
by: Alexandre Chicheportiche, et al.
Published: (2018-12-01)

Characterisation of a hand-held CZT-based gamma camera for 177Lu imaging
by: Daniel Roth, et al.
Published: (2020-07-01)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code
by: Milad Peer-Firozjaei, et al.
Published: (2021-06-01)

Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01)

Preliminary Dosimetry Study of 67Ga-AATS for Human Based on Biodistribution Data in Rats
by: Hassan Yousefnia, et al.
Published: (2015-07-01)

Preliminary Dosimetry Study of 67Ga-AATS for Human Based on Biodistribution Data in Rats
by: Hassan Yousefnia, et al.
Published: (2015-07-01)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
by: Alexander R. Haug
Published: (2020-04-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Spectral Comparison of Neutron-Irradiated Natural and Enriched Ytterbium Targets for Lu-177 Production
by: M. Maiyesni, et al.
Published: (2019-11-01)